Disclosure of payment completion for 2,932,000 new shares issued through a third-party allotment. Also, 29,320 stock acquisition rights allocated on the same date, with capital increase of approximately 410.48 million yen and funds raised of approximately 549.46 million yen. Allottee: CVI Investments, Inc. Exercise period from 2026-09-04 to 2030-09-03.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4978","jir_company_name":"ReproCELL Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4978-20260903-01.pdf","jir_short_summary":"Disclosure of payment completion for 2,932,000 new shares issued through a third-party allotment. Also, 29,320 stock acquisition rights allocated on the same date, with capital increase of approximately 410.48 million yen and funds raised of approximately 549.46 million yen. Allottee: CVI Investments, Inc. Exercise period from 2026-09-04 to 2030-09-03.","jir_summary":"### Section Heading\nThis release reports the completion of payment for the issuance of new shares under the Equity Program as the third third-party allotment and the payment completion for the 19th stock acquisition rights. Allottee is CVI Investments, Inc., with an issue price of 140 yen per share and issued shares totaling 2,932,000. The capital amount is 205,240,000 yen, and the capital surplus is the same amount. The stock acquisition rights total 29,320 units, with an exercise period from September 4, 2026 to September 3, 2030. The total funds raised are expected to be approximately 54.9 million yen.\n\n### Section 2 Heading\nThe allocation method is a third-party allotment, with the allottee being CVI Investments, Inc., announced on the same date as payment completion. The exercise price is 186 yen, and the potential number of shares is 2,932,000 (one stock acquisition right corresponds to 100 shares). The calculation basis uses the funding amount assuming no adjustment to the exercise price; actual funds raised may vary depending on future exercise status and market conditions.","jir_financial_highlights":"Number of issued ordinary shares: 2,932,000 shares (Unknown)\nIssue price: 140 yen (Unknown)\nAmounts raised: 410,480,000 yen (Unknown)\nOverview of the new stock acquisition rights issuance (total): 4,104,800 yen (Unknown)\nAssumed funds raised (upon exercise of stock acquisition rights): 549,456,800 yen (Unknown)","jir_category":"","jir_hashtags":"#ReproCELL, #capital_policy, #new_share issuance, #stock_acquisition_rights, #third_party_allotment","jir_key_figures":"2,932,000 shares: Issued ordinary shares\n140 yen: Issuance price\n410,480,000 yen: Amount raised\n29,320 units: Issued stock acquisition rights\n186 yen: Exercise price\n549,456,800 yen: Potential funding amount based on assumed number of underlying shares","jir_meta_title":"\u3010ReproCELL\u3011 Announcement of payment completion for new shares and stock acquisition rights issued through third-party allotment | September 2026","jir_meta_description":"ReproCELL announces payment completion for 2,932,000 new shares issued under the Third-Party Allotment of Equity Program and the allotment of the 19th stock acquisition rights. Allottee: CVI Investments, Inc. Increases in capital and capital surplus are both 205 million yen. Exercise period: 2026-09-04 to 2030-09-03. For details, please refer to the IR materials.","jir_og_title":"\u3010ReproCELL\u3011 Announcement of payment completion for new shares issued through third-party allotment | September 2026","jir_og_description":"ReproCELL announces payment completion for new shares and stock acquisition rights issued through a third-party allotment. Allottee: CVI Investments, Inc.; capital increase amount about 205 million yen; exercise period 2026\u20132030.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58459,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-110565","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n